Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma

In patients with metastatic renal cell cancer, based on limited evidence, increased sunitinib exposure is associated with better outcome. The survival and toxicity data of patients receiving individualized dose escalated sunitinib therapy as compared to standard management were analyzed in this study.